AnaptysBio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ANAB Nasdaq 2836 www.anaptysbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AnaptysBio, Inc.

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - Dec 15th, 2025 5:00 am
J.P. Morgan Maintains a Sell Rating on GSK plc (GSK) - Dec 10th, 2025 9:28 am
The Bull Case For AnaptysBio (ANAB) Could Change Following Jemperli Legal Clash With GSK Subsidiary - Dec 2nd, 2025 11:11 am
Anaptys Announces Participation in December Investor Conferences - Nov 25th, 2025 2:15 pm
AnaptysBio Presents Opportunity Despite 'Near-Term Turbulence' Amid Legal Dispute with GSK, Wedbush Says - Nov 24th, 2025 5:32 am
AnaptysBio Reverses Higher After Trading Legal Barbs With Pharma Giant GSK - Nov 21st, 2025 2:46 pm
Rate Cut Hopes Lift US Equity Futures Pre-Bell - Nov 21st, 2025 7:10 am
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday on Reignited Rate Cut Hopes - Nov 21st, 2025 6:57 am
GSK, AnaptysBio Sue Each Other Over Cancer Drug License - Nov 21st, 2025 4:14 am
Anaptys Announces $100 Million Stock Repurchase Plan - Nov 21st, 2025 2:00 am
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary - Nov 21st, 2025 1:50 am
Assessing AnaptysBio (ANAB) Valuation After Ulcerative Colitis Trial Discontinuation - Nov 20th, 2025 1:15 am
Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer data - Nov 12th, 2025 3:20 am
Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run - Nov 10th, 2025 2:53 pm
Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis - Nov 10th, 2025 7:00 am
AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates - Nov 4th, 2025 3:50 pm
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update - Nov 4th, 2025 2:15 pm
Anaptys Announces Participation in November Investor Conferences - Nov 4th, 2025 2:15 pm
A Look at AnaptysBio's (ANAB) Valuation Following Promising Phase 2b Rosnilimab Results and Analyst Upgrades - Nov 1st, 2025 6:10 am
Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy? - Oct 29th, 2025 8:00 am